News News

CONTACT:

Sirnaomics, Inc.
Michael Molyneaux MD MBA
Chief Medical Officer
michaelmolyneaux@sirnaomics.com

ICR Healthcare

Investors: Stephanie Carrington
Tel: +1 646 277 1282
Stephanie.Carrington@icrinc.com

Media: Mark Corbae
Tel: 203-682-8288
Email: Mark.Corbae@icrinc.com

June 20, 2020 Sirnaomics and Precision NanoSystems Have Formed a Partnership

Developing and Manufacturing Novel RNAi drug Candidates Using Precision NanoSystems’ NxGen™ Platform Sirnaomics Inc. (Sirnaomics) and Precision…

June 11, 2020 Sirnaomics Announces Decision to Spin off RNAimmune to Develop Novel mRNA Therapeutics and Vaccines

Sirnaomics, Inc., a leading biopharmaceutical company engaged in the discovery and development of RNAi therapeutics, today announced…

April 9, 2020 Sirnaomics Announces Positive Topline Results from Interim Analysis of Ongoing Phase II Clinical Trial Evaluating STP705 in Cutaneous Squamous Cell Carcinoma in situ (isSCC)

Sirnaomics Inc., a leading biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer…

March 20, 2020 Industry, academia pivot: Pipeline of COVID-19 vaccine and therapeutic candidates doubles

A list of biopharma companies and nonprofit entities, including academia, working feverishly to find a vaccine or…

February 19, 2020 Hunt for New Coronavirus Treatments Includes Gene-Silencing and Monoclonal Antibodies

Viral infections can be very hard to treat. Just ask anyone who has a bad case of…

1 2 3 10